[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Editorial Board::
Executive Members::
Instruction to Authors::
Peer Review::
Articles Archive::
Indexing Databases::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Search published articles ::
Showing 1 results for Nikofar

A Basi , Ar Nikofar , H Azhdarkosh , P Ordoni Aval , Z Ordoni Aval ,
Volume 19, Issue 2 (7-2017)
Abstract

Background and Objective: Squamous carcinoma accounts for the majority of esophageal carcinoma worldwide. This study was done to evaluate the survival rate of patients with esophageal cancer in Iran.

Methods: This historical cohort study was carried outon 105 patients with esophageal squamous cell carcinoma whom admitted to Firoozgar hospital in Tehran, Iran during 2009-14. Patients with esophageal squamous cell carcinoma were treated with chemoradiation either with or without surgery.

Results: The mean age of patients was 63 years. Frequency of esophageal cancer in both sexes in the age group 51-60 years was higher than other groups. 5-year survival in patients with esophageal cancer treated with chemoradiation without surgery was 9.5% and in patients treated with chemoradiation with surgery was 31.7 % (P<0.05). One-year, three-year and five-year survival rate in patients were treated with chemoradiation with or without surgery was 68.5%, 38% and 22.8%, respectively.

Conclusion: The survival rate of patients with esophageal cancer is very low, but the treatment with chemoradiation with surgery can increase life expectancy of patients.



Page 1 from 1     

مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.11 seconds with 25 queries by YEKTAWEB 4660
Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)